Quintiles Appoints New Global Head of Phase I Division

Former Quintiles Chief Medical and Scientific Officer, Dr. Oren Cohen, Tapped to Lead Global Phase I Clinical Research Division

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Quintiles today announced that Oren Cohen, M.D., will serve as Senior Vice President and Global Head of its Phase I Clinical Research division, which includes world-class facilities in Overland Park, Kansas (U.S.), London (U.K.) and Hyderabad (India). Cohen will leverage Quintiles’ breadth of clinical trial services and deep expertise in biomarker development to provide sponsors with an integrated early clinical development platform that reduces overall study costs, simplifies trial management and accelerates development, while ensuring quality and patient safety.

Oren Cohen, SVP and Global Head, Quintiles Phase I (Photo: Business Wire)

Oren Cohen, SVP and Global Head, Quintiles Phase I (Photo: Business Wire)

“Oren brings a deep understanding of the patient and a wealth of clinical and scientific expertise from his tenure as Quintiles’ Chief Medical and Scientific Officer (CMSO),” said Paula Brown Stafford, President of Quintiles Clinical Development. “Under Oren’s leadership, Quintiles will effectively help our customers navigate the New Health through a seamlessly integrated early clinical development offering that is world-class, both in terms of infrastructure and intellectual capital.”

Cohen received his M.D. from Duke University School of Medicine, and completed his internship and residency in internal medicine at The New York Hospital – Cornell Medical Center. He completed a fellowship in infectious diseases at the National Institute of Allergy and Infectious Diseases (NIAID), and then held several scientific and administrative positions within NIAID. Cohen joined Quintiles as a medical advisor in 2001 and was appointed CMSO in 2004. He is Consulting Professor of Medicine at Duke University Medical Center and is a Fellow of the Infectious Diseases Society of America.

“The Phase I clinical research space is changing rapidly, with fewer new molecules entering development and a fundamental shift in target study populations from healthy volunteers to patient groups,” said Cohen. “Biopharma companies are looking for an ally to help them manage these complexities, ensure patient safety and reduce costs, and Quintiles offers best-in-class early clinical development solutions to meet our customers’ needs.”

About Quintiles

Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of more than 20,000 engaged professionals in 60 countries works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6846137&lang=en



CONTACT:

Quintiles
Jay Johnson, Corporate Communications
919-998-2091
[email protected]
or
Greg Connors, Investor Relations
919-998-2000
[email protected]

KEYWORDS:   United States  North America  North Carolina

INDUSTRY KEYWORDS:   Health  Clinical Trials  Hospitals  Pharmaceutical  Other Health  Research  Other Science  Science

MEDIA:

Logo
 Logo
Photo
 Photo
Oren Cohen, SVP and Global Head, Quintiles Phase I (Photo: Business Wire)

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.